MDCXW Medicus Pharma Ltd. - Warrant
MDCXW Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
MDCXW Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 11
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $8M | $4M | $193.6K | |
| SG&A Expense | $18M | $8M | $5M | |
| Operating Expenses | $34M | $11M | $5M | |
| Operating Income | $-34M | $-11M | $-5M | |
| Other Non-op | $-1M | $25.4K | $-584.8K | |
| Income Tax | $0 | $0 | $0 | |
| Net Income | $-47M | $-11M | $-5M | |
| EPS (Basic) | $-2.74 | $-1.16 | $-1.53 | |
| EPS (Diluted) | $-2.74 | $-1.16 | $-1.53 | |
| Shares (Basic) | 17,283,824 | 9,619,184 | 3,479,494 | |
| Shares (Diluted) | 17,283,824 | 9,619,184 | 3,479,494 |
Balance general 15
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $9M | $4M | $2M | |
| Prepaid Expense | $1M | $1M | $173.7K | |
| Current Assets | $10M | $5M | $2M | |
| Total Assets | $10M | $6M | $2M | |
| Accounts Payable | $3M | $1M | $210.8K | |
| Current Liabilities | $10M | $2M | $781.6K | |
| Capital Leases | $60.1K | $205.9K | $0 | |
| Total Liabilities | $10M | $3M | $781.6K | |
| Common Stock | $57M | $31M | $19M | |
| Paid-in Capital | $7M | $2M | $98.6K | |
| Retained Earnings | $-64M | $-29M | $-18M | |
| AOCI | $10.9K | $0 | · | |
| Stockholders' Equity | $-67.6K | $3M | $1M | |
| Liabilities + Equity | $10M | $6M | $2M | |
| Shares Outstanding | 25,176,303 | 11,816,721 | 8,076,673 |
Flujo de Efectivo 7
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $2M | $713.1K | $98.6K | |
| Deferred Tax | $0 | $0 | · | |
| Operating Cash Flow | $-23M | $-10M | $-4M | |
| Investing Cash Flow | $-5M | $0 | · | |
| Stock Issued | $10M | $5M | $0 | |
| Financing Cash Flow | $32M | $13M | $6M | |
| Net Change in Cash | $5M | $2M | · |
Valoración (TTM) 4
| Métrica | Tendencia | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue TTM | $-197.4K | $25.4K | · | |
| Net Income TTM | $-47M | $-11M | · | |
| P/E | -0.9 | · | · | |
| Earnings Yield | -109.6% | · | · |
Estado de resultados 12
| Métrica | Tendencia | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $5M | $3M | $2M | $1M | $2M | $1M | |
| SG&A Expense | $7M | $10M | $5 | $5M | $3M | $2M | |
| Operating Expenses | $11M | $23M | $15 | $6M | $5M | $4M | |
| Operating Income | $-11M | $-23M | $-15 | $-6M | $-5M | $-4M | |
| Interest Expense | $205.6K | · | · | $0 | · | · | |
| Other Non-op | $-205.6K | $-394.0K | $-555.0K | $-160.0K | $23.9K | $48.9K | |
| Net Income | $-12M | $-15M | $-21M | $-6M | $-5M | $-4M | |
| EPS (Basic) | $-0.21 | $-0.77 | $-1.12 | $-0.43 | $-0.42 | $-0.27 | |
| EPS (Diluted) | $-0.21 | $-0.77 | $-1.12 | $-0.43 | $-0.42 | $-0.27 | |
| Shares (Basic) | 55,055,225 | -27,872,542 | 18,631,668 | 14,284,261 | 12,240,437 | -16,140,220 | |
| Shares (Diluted) | 55,055,225 | -27,872,542 | 18,631,668 | 14,284,261 | 12,240,437 | -16,140,220 | |
| EBITDA | $-11M | · | $-15 | $-6M | $-5M | · |
Balance general 15
| Métrica | Tendencia | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $9M | $9M | $10M | $4M | $4M | |
| Prepaid Expense | $2M | $1M | $1M | $1M | $1M | $1M | |
| Current Assets | $17M | $10M | $10M | $11M | $5M | $5M | |
| Total Assets | $27M | $10M | $10M | $12M | $6M | $6M | |
| Accounts Payable | $7M | $3M | $2M | $2M | $2M | $1M | |
| Current Liabilities | $11M | $10M | $11M | $9M | $3M | $2M | |
| Capital Leases | $0 | $60.1K | $95.2K | $141.8K | $174.4K | $205.9K | |
| Total Liabilities | $29M | $10M | $11M | $9M | $4M | $3M | |
| Common Stock | $74M | $57M | $4 | $38M | $33M | $31M | |
| Paid-in Capital | $9M | $7M | $6M | $6M | $3M | $2M | |
| Retained Earnings | $-85M | $-64M | $-5 | $-40M | $-34M | $-29M | |
| AOCI | $61.1K | $10.9K | $10.7K | · | · | $0 | |
| Stockholders' Equity | $-2M | $-67.6K | $-910.1K | $3M | $2M | $3M | |
| Liabilities + Equity | $27M | $10M | $10M | $12M | $6M | $6M | |
| Shares Outstanding | 60,168,044 | 25,176,303 | 20,971,122 | 15,936,266 | 13,417,561 | 11,816,721 |
Flujo de Efectivo 6
| Métrica | Tendencia | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $429.7K | $852.8K | $117.4K | $112.3K | $91.7K | |
| Operating Cash Flow | $-7M | $-7M | $-7M | $-5M | $-4M | $-3M | |
| Investing Cash Flow | · | $0 | · | · | · | $0 | |
| Stock Issued | $0 | $0 | $0 | $6M | · | $0 | |
| Financing Cash Flow | $26M | $7M | $10M | $11M | $4M | $2M | |
| Net Change in Cash | $19M | $43.1K | $-1M | $6M | · | $-1M |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -0.13% | -15038.7% | · | · | |
| Net Margin | · | · | -180917.3% | · | · | · | |
| EBITDA Margin | · | · | -0.13% | -15038.7% | · | · | |
| ROA | -59.5% | · | -419.7% | · | -180.4% | · | |
| ROE | -1564.6% | · | 4600.6% | · | -475.2% | · |
Liquidez y Solvencia 3
| Métrica | Tendencia | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | · | 0.9 | 1.3 | 1.5 | · | |
| Quick Ratio | 1.4 | · | 0.8 | 1.1 | 1.2 | · | |
| Interest Coverage | -55.8 | · | · | · | · | · |
Eficiencia 1
| Métrica | Tendencia | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | · | · |
Valoración (TTM) 6
| Métrica | Tendencia | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-48M | · | · | · | · | · | |
| Market Cap | $41M | · | $52M | $40M | · | · | |
| P/E | -0.3 | · | -1.1 | -1.6 | · | · | |
| P/B | -23.2 | · | -57.6 | 12.3 | · | · | |
| P / Tangible Book | · | · | · | 12.3 | · | · | |
| Earnings Yield | -304.6% | · | -88.4% | -61.2% | · | · |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Beneficio neto | $-47M | $-11M | $-5M |
| EPS Diluido | $-2.74 | $-1.16 | $-1.53 |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 4 declarantes · $64K total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 0 (-1 vs trimestre anterior) | 2 (+2 vs trimestre anterior) | 1 (+1 vs trimestre anterior) | 0 (0 vs trimestre anterior) | -60K |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | $39 390 | 60 600 | 61,89% | Acciones |
| Anson Funds Management LP | $18 923 | 42 400 | 29,73% | Acciones |
| Connective Capital Management, LLC | $3 900 | 6 000 | 6,13% | Acciones |
| UBS Group AG | $1 432 | 2 203 | 2,25% | Acciones |